scholarly journals Homogeneous antibody-drug conjugates via site-selective disulfide bridging

2018 ◽  
Vol 30 ◽  
pp. 11-20 ◽  
Author(s):  
Nafsika Forte ◽  
Vijay Chudasama ◽  
James R. Baker
Keyword(s):  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Disulfide Bridging ◽  
Site Selective ◽  
Antibody Drug

ChemInform Abstract: Construction of Homogeneous Antibody-Drug Conjugates Using Site-Selective Protein Chemistry

ChemInform ◽  
2016 ◽  
Vol 47 (25) ◽  
Author(s):  
Padma Akkapeddi ◽  
Saara-Anne Azizi ◽  
Allyson M. Freedy ◽  
Pedro M. S. D. Cal ◽  
Pedro M. P. Gois ◽  
...  
Keyword(s):  
Protein Chemistry ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Site Selective ◽  
Antibody Drug

scholarly journals A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody–drug conjugates

2019 ◽  
Vol 10 (3) ◽  
pp. 694-700 ◽  
Author(s):  
Stephen J. Walsh ◽  
Soleilmane Omarjee ◽  
Warren R. J. D. Galloway ◽  
Terence T.-L. Kwan ◽  
Hannah F. Sore ◽  
...  
Keyword(s):  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Native Proteins ◽  
Site Selective ◽  
Antibody Drug

Divinylpyrimidine (DVP) linkers enable access to highly stable and functional antibody–drug conjugates.

scholarly journals Site-selective modification strategies in antibody–drug conjugates

2021 ◽  
Author(s):  
Stephen J. Walsh ◽  
Jonathan D. Bargh ◽  
Friederike M. Dannheim ◽  
Abigail R. Hanby ◽  
Hikaru Seki ◽  
...  
Keyword(s):  
Cell Types ◽  
Specific Cell ◽  
Antibody Drug Conjugates ◽  
Specific Targeting ◽  
Drug Conjugates ◽  
Site Selective ◽  
Antibody Drug ◽  
Made In

Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an antibody to deliver a cytotoxic payload to specific cell types. This review summarises the advances made in the construction of homogenous ADCs.

scholarly journals Correction: A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody–drug conjugates

2019 ◽  
Vol 10 (2) ◽  
pp. 633-634
Author(s):  
Stephen J. Walsh ◽  
Soleilmane Omarjee ◽  
Warren R. J. D. Galloway ◽  
Terence T.-L. Kwan ◽  
Hannah F. Sore ◽  
...  
Keyword(s):  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Native Proteins ◽  
Site Selective ◽  
Antibody Drug

Correction for ‘A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody–drug conjugates’ by Stephen J. Walsh et al., Chem. Sci., 2019, DOI: 10.1039/c8sc04645j.

scholarly journals Construction of homogeneous antibody–drug conjugates using site-selective protein chemistry

2016 ◽  
Vol 7 (5) ◽  
pp. 2954-2963 ◽  
Author(s):  
Padma Akkapeddi ◽  
Saara-Anne Azizi ◽  
Allyson M. Freedy ◽  
Pedro M. S. D. Cal ◽  
Pedro M. P. Gois ◽  
...  
Keyword(s):  
Therapeutic Efficacy ◽  
Protein Chemistry ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Drug Conjugation ◽  
Selective Chemical ◽  
Site Selective ◽  
Antibody Drug

The use of site-selective chemical drug-conjugation strategies enables the construction of antibody–drug conjugates (ADCs) with superior therapeutic efficacy.”

scholarly journals Site-selective lysine conjugation methods and applications towards antibody–drug conjugates

2021 ◽  
Author(s):  
Muhammed Haque ◽  
Nafsika Forte ◽  
James R. Baker
Keyword(s):  
Recent Work ◽  
Feature Article ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Lysine Modification ◽  
Site Selective ◽  
Antibody Drug

In this feature article we discuss developments in site-selective lysine modification methodologies and their application towards the synthesis of antibody–drug conjugates; including our recent work on a cysteine-to-lysine transfer (CLT) protocol.

ASCO-GU 2019: Metastasierte Urothelkarzinome

2019 ◽  
Vol 10 (03) ◽  
pp. 140-141
Author(s):  
Alexander Kretzschmar
Keyword(s):  
San Francisco ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Chapel Hill ◽  
Antibody Drug

Die Therapielandschaft des metastasierten Urothelkarzinoms hat sich seit der Zulassung der ersten Immun-Checkpoint-Inhibitoren verändert. Die neuen Therapien sind deutlich effektiver, allerdings erreichen die Responseraten der neuen Therapien nur bis zu etwa 30 %, beklagte Prof. Matthew Milowsky, Chapel Hill/USA, auf einer Oral Abstract Session auf dem ASCO-GU. In San Francisco gaben erste Vorträge und Poster bereits einen Einblick, wovon diejenigen Patienten profitieren könnten, die auf die etablierten Chemotherapien und die neuen Immuntherapien nicht ansprechen. Manche Onkologen sprechen bereits von der „Post-Checkpoint-Ära”. Als Kandidaten werden vor allem Antikörper-Wirkstoff-Konjugate (antibody-drug conjugates; ADC) gehandelt – und zwar nicht nur zur Therapie des metastasierten Blasenkarzinoms.

Sign in / Sign up

Export Citation Format

Share Document